Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Amryt Pharma

Biotech & Life Sciences · Dublin, Ireland · Founded 2004 · IPO 2012 Unicorn

Develops and delivers treatments for patients with rare and orphan diseases.

Valuation
$1.25B
Market cap · 2026
Revenue
$223M
Latest reported FY
EBITDA
$68M
Latest reported FY

Investors

6 investors on Amryt Pharma's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 6 investors entered at this stage
Abingworth
XT Investments
7 Health Ventures
MPM BioImpact
F2 Ventures
ARCH Venture Partners

Global footprint

Where Amryt Pharma has talent and traffic

Workforce by country
14 countries with
team presence
🇮🇪 Ireland55.6%
🇺🇸 United States12.6%
🇮🇱 Israel4.7%
🇨🇴 Colombia4.7%
🇸🇦 Saudi Arabia4.7%
Top 5 of 14 shown
Web traffic by country
290 monthly visits
across markets
🇮🇳 India103.4%
Top 1 markets shown

Patent intelligence

$184M patent portfolio · 53 active families

Estimated portfolio value
$184M
14.7% of market cap · 2.4× smaller than top peer Alexion Pharmaceuticals ($444M)
53 active patent families
Where Amryt Pharma innovates DiseaseCombination therapyMolecular biologyOral administrationAcromegaly

Where Amryt Pharma concentrates vs peers

Each axis is a top-10 topic across Amryt Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Amryt Pharma's 4 investments and acquisitions.

Every disclosed deal where Amryt Pharma appeared as a backer or acquirer, 2016–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Amryt Pharma's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Amryt Pharma's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Amryt Pharma

        An AI-synthesized read of the highest-engagement posts about Amryt Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Amryt Pharma on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.